Globalpharma secures technology transfer license to manufacture additional product lines

The conclusion of this agreement allows Globalpharma, through the transfer of a technology license, to manufacture and distribute products for the treatment of respiratory tract conditions such as asthma, as well as gynaecologic and immunity related conditions.

Polichem S.A. is a private pharmaceutical Company based in Lugano, Switzerland, with a long tradition of activity in the pharmaceutical field, having historical roots in Italy since 1947. The Company focuses on the development, registration, distribution and licensing of innovative pharmaceutical products, with its core business in the fields of Gynaecology, Dermatology, Cardiovascular and Central Nervous System.

Polichem licences and exports to four continents and more than 30 countries through its international network of competent partners, holding licensing and distribution agreements for its products with international and major national companies. 80 percent of sales are made in Europe and 20 percent in the rest of the World.

Mr Khalid Bin Kalban, Managing Director and Chief Executive Officer of Dubai Investments PJSC and Chairman of Globalpharma comments,

"We are excited about the transfer of technology agreement with Polichem S.A. Polichem are well respected for creating new and exciting product lines based on their own in-house research program. We look forward to including these product lines in Globalpharma's portfolio."

Mr. Abdelhamid Boutefah, Area Manger, Polichem S.A. adds, "Today's agreement is of great significance for Polichem S.A., further strengthening our position outside of our core market, Europe. We are confident that the technologies developed at Polichem S.A. will significantly benefit healthcare professionals and patients in the Middle East."

Dr. Maged Amer, General Manager, Globalpharma adds, "The strengthening of our product lines in Middle Eastern markets with the help of the Mackenzie & Stuart Group continues to be of key importance for Globalpharma. This technology provides us with the opportunity to penetrate into new markets such as Libya and Iraq with exciting new product offerings."